Charts

These two growth stocks could be worthwhile buy-and-holds.

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Norwegian Cruise Line Holdings Ltd (NCLH), where a total of 53,252 contracts have traded so far, representing approximately 5.3 million underlying shares. That amounts to about 45.6% of NCLH's average daily trading volume over the past month of 11.7 million shares..

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Nasdaq Pharmaceuticals ETF (FTXH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $31.95 per unit.

Gainers Bionomics (NASDAQ:BNOX) stock increased by 261.4% to $3.56 during Thursday's regular session. As of 13:30 EST, Bionomics's ...

Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on September 8, 2023, the Compensation Committee of Acadia’s Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 23,749 shares of common stock and 14,306 restricted stock units (“RSUs”) to 14 new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications. Mr. Kildani will be responsible for leading investor relations and corporate communications and serve as a member of the company’s Executive Management Committee. He will report to Mark Schneyer, Executive Vice President, Chief Financial Officer of Acadia.

ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) is possibly approaching a major achievement in its business, so we would...

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Acadia Pharmaceuticals Inc (ACAD), where a total of 10,757 contracts have traded so far, representing approximately 1.1 million underlying shares. That amounts to about 91.8% of ACAD's average daily trading volume over the past month of 1.2 million shares..

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Acadia Pharmaceuticals Inc (ACAD) was identified as having a larger market cap than the smaller end of the S&P 500, for example DXC Technology Co (DXC), according to The Online Investor. Click here to find out the top S&P 500 components ordered by average analyst rating » Market capitalization is an important data point for investors to keep an eye on, for various reasons..

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:

A top hedge fund has been steadily buying these two growth stocks in 2023.

Over the past 3 months, 18 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ:ACAD) stock. These analysts are ...

This biotech stock has been on fire in 2023.

This small-cap biotech might be a hidden gem.

JP Morgan has decided to maintain its Neutral rating of ACADIA Pharmaceuticals (NASDAQ:ACAD) and raise its price target from $28.00 to ...

Puma Biotechnology (PBYI) beats second-quarter earnings and sales estimates. Stock rises in after-hours.

Within the last quarter, ACADIA Pharmaceuticals (NASDAQ:ACAD) has observed the following analyst ratings: Bullish Somewhat ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2023.

ACADIA Pharmaceuticals (NASDAQ:ACAD) is set to give its latest quarterly earnings report on Wednesday, 2023-08-02. Here's what investors ...

Investors in Acadia Pharmaceuticals Inc (ACAD) saw new options become available this week, for the March 2024 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 228 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

Biogen (BIIB) beats second-quarter estimates for earnings and sales. It maintains 2023 guidance. Stock up in pre-market.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the appointment of Dr. Kevin R. Oliver as Senior Vice President, Chief Business Officer, effective July 10, 2023. Dr. Oliver will oversee all business development functions and will serve as a member of the company’s Executive Management Committee, reporting to Steve Davis, President and Chief Executive Officer of Acadia.

Investors considering a purchase of Acadia Pharmaceuticals Inc (ACAD) stock, but cautious about paying the going market price of $30.14/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2024 put at the $24 strike, which has a bid at the time of this writing of $1.45..

Here is how Acadia Pharmaceuticals (ACAD) and Abbott (ABT) have performed compared to their sector so far this year.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter financial results on Wednesday, August 2, 2023, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 2, 2023, at 4:30 p.m. Eastern Time to discuss financial results and operations.

Celebrations may be in order for ACADIA Pharmaceuticals Inc. ( NASDAQ:ACAD ) shareholders, with the analysts delivering...

U.S. stocks traded mixed toward the end of trading, with the S&P 500 and Nasdaq Composite moving lower on Friday. The Dow traded ...

Acadia Pharmaceuticals Inc(NASDAQ: ACAD) expanded its current licensing agreement for trofinetide withNeuren ...

Gainers PainReform Ltd. (NASDAQ: PRFX) shares climbed 103% to $11.67. PainReform recently announced pricing of a $2.7 million ...

U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Friday. The Dow traded up 0.31% to ...

Investors are cheering Acadia's latest news.

Acadia obliterated expectations for the launch quarter of its Rett Syndrome treatment and, on Friday, ACAD stock hit a two-year high.

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in ...

Acadia Pharmaceuticals Inc(NASDAQ: ACAD) shares are trading higher after the company expanded its current licensing agreement for ...

Gainers Ainos, Inc. (NASDAQ: AIMD) shares surged 108.2% to $1.52 in pre-market trading after gaining around 7% on ...

Keybanc boosted the price target for Spotify Technology S.A. (NYSE: SPOT) from $180 to $205. Keybanc analyst Justin Patterson ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time to start the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live Wall Street Titan: Here’s My #1 Stock for 2023 The $1 Investment You MUST Take Advantage of Right Now It doesn’t matter if you have $500 or $5 million. Do this now.

Acadia Pharmaceuticals, Roivant, Leslie's, Nokia and Ericsson were among the biggest moving shares ahead of Friday's market open.

Markets kept powering higher on the day.

Gainers Ainos (NASDAQ:AIMD) shares increased by 84.9% to $1.35 during Thursday's after-market session. At the close, Ainos's trading ...

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it has expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ex-North American rights to the drug as well as global rights in Rett syndrome and Fragile X syndrome to Neuren’s development candidate NNZ-2591. In April of this year, Acadia launched trofinetide in the United States under the brand name DAYBUE as the first and only drug approved for the treatment of Rett syndrome.

Analysts have provided the following ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) within the last quarter: Bullish Somewhat ...

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track ...

Tuesday,Acadia Pharmaceuticals Inc(NASDAQ: ACAD) announced the addition of a new Phase 3 development candidate to its rare ...

Over the past 3 months, 11 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ:ACAD) stock. These analysts are ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the addition of a new Phase 3 development candidate to its rare disease portfolio, ACP-101 (intranasal carbetocin), for the treatment of hyperphagia (a false and unrelenting state of starvation) in Prader-Willi syndrome (PWS). Acadia acquired worldwide rights to develop and commercialize ACP-101 with the acquisition of Levo Therapeutics in June 2022.

When we invest, we're generally looking for stocks that outperform the market average. And in our experience, buying...

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Acadia Pharmaceuticals Inc (ACAD) was identified as having a larger market cap than the smaller end of the S&P 500, for example Lincoln National Corp. (LNC), according to The Online Investor..

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Nature Medicine published results from the pivotal Phase 3 LAVENDER™ trial, a 12-week randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of DAYBUE™ in patients with Rett syndrome five to 20 years of age.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Penny stocks can be rewarding. Look at Acadia Pharmaceuticals (NASDAQ:ACAD), for example. In 2012, it was working on a treatment for Parkinson’s Disease Psychosis and traded for less than $1. By 2015, it was up to $43 a share, a 4,200% return. Apple (NASDAQ:AAPL), Ford Motor (NYSE:F), Advanced Micro Devices (NASDAQ:AMD) and even Novavax (NASDAQ:NVAX) were.... The post 3 Penny Stocks That Could Skyrocket in the Next 12 Months appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live Wall Street Titan: Here’s My #1 Stock for 2023 The $1 Investment You MUST Take Advantage of Right Now It doesn’t matter if you have $500 or $5 million. Do this now.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Jefferies Global Healthcare Conference on Wednesday, June 7, 2023 at 10:00 a.m. Eastern Time in New York, NY.